Trypanosoma Cruzi Cyp51 Inhibitor Derived from a Mycobacterium Tuberculosis Screen Hit.
Chen, C.-K., Doyle, P.S., Yermalitskaya, L.V., Mackey, Z.B., Ang, K.K.H., Mckerrow, J.H., Podust, L.M.(2009) PLoS Negl Trop Dis 3: E372
- PubMed: 19190730 
- DOI: https://doi.org/10.1371/journal.pntd.0000372
- Primary Citation of Related Structures:  
2W09, 2W0A, 2W0B - PubMed Abstract: 
The two front-line drugs for chronic Trypanosoma cruzi infections are limited by adverse side-effects and declining efficacy. One potential new target for Chagas' disease chemotherapy is sterol 14alpha-demethylase (CYP51), a cytochrome P450 enzyme involved in biosynthesis of membrane sterols.
Organizational Affiliation: 
Department of Pharmaceutical Chemistry, University of California, San Francisco, California, United States of America.